Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan
· Delayed Price · Currency is TWD 20.00
-0.05 (-0.25%)
Mar 10, 2026, 1:41 PM CST
Anxo Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 883.22 | 895.32 | 939.94 | 866.27 | 824.1 | 866.11 | Upgrade
|
| Revenue Growth (YoY) | -2.90% | -4.75% | 8.50% | 5.12% | -4.85% | -1.35% | Upgrade
|
| Cost of Revenue | 558.5 | 569.84 | 543.01 | 534.82 | 492.44 | 509.82 | Upgrade
|
| Gross Profit | 324.72 | 325.48 | 396.93 | 331.46 | 331.66 | 356.29 | Upgrade
|
| Selling, General & Admin | 221.98 | 233.48 | 204.58 | 185.66 | 180.43 | 198.61 | Upgrade
|
| Research & Development | 149.78 | 148.43 | 139.2 | 139.59 | 111.38 | 100.56 | Upgrade
|
| Operating Expenses | 372.69 | 382.06 | 343.62 | 325.51 | 291.56 | 299.31 | Upgrade
|
| Operating Income | -47.97 | -56.57 | 53.31 | 5.95 | 40.1 | 56.98 | Upgrade
|
| Interest Expense | -16.54 | -16.68 | -18.08 | -15.19 | -12.76 | -14.19 | Upgrade
|
| Interest & Investment Income | 4.7 | 5.57 | 3.89 | 1.65 | 1.12 | 0.72 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.53 | 2.48 | -1.65 | 1.09 | -6.48 | 3.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.58 | 5.18 | 1.2 | 1.33 | 2.38 | 0.58 | Upgrade
|
| EBT Excluding Unusual Items | -51.76 | -60.02 | 38.67 | -5.18 | 24.35 | 47.58 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.35 | - | 0.01 | 0.47 | -0.08 | 1.33 | Upgrade
|
| Asset Writedown | - | - | - | - | 0.06 | - | Upgrade
|
| Pretax Income | -52.11 | -60.02 | 38.68 | -4.71 | 24.33 | 48.91 | Upgrade
|
| Income Tax Expense | -9.02 | -5.92 | 7.88 | 2.33 | 4.59 | 10.3 | Upgrade
|
| Earnings From Continuing Operations | -43.09 | -54.1 | 30.8 | -7.04 | 19.74 | 38.61 | Upgrade
|
| Minority Interest in Earnings | 0.75 | -3.11 | -8.94 | -5.52 | -0.51 | -7.2 | Upgrade
|
| Net Income | -42.34 | -57.21 | 21.86 | -12.56 | 19.23 | 31.4 | Upgrade
|
| Net Income to Common | -42.34 | -57.21 | 21.86 | -12.56 | 19.23 | 31.4 | Upgrade
|
| Net Income Growth | - | - | - | - | -38.75% | 30.21% | Upgrade
|
| Shares Outstanding (Basic) | 56 | 56 | 51 | 48 | 48 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 56 | 52 | 48 | 48 | 48 | Upgrade
|
| Shares Change (YoY) | 2.25% | 8.00% | 7.11% | -0.66% | 0.88% | 7.05% | Upgrade
|
| EPS (Basic) | -0.76 | -1.03 | 0.43 | -0.26 | 0.40 | 0.65 | Upgrade
|
| EPS (Diluted) | -0.76 | -1.03 | 0.42 | -0.26 | 0.40 | 0.65 | Upgrade
|
| EPS Growth | - | - | - | - | -38.56% | 21.88% | Upgrade
|
| Free Cash Flow | 28.68 | 69.63 | -60.48 | 56.68 | 43.51 | 43.9 | Upgrade
|
| Free Cash Flow Per Share | 0.51 | 1.25 | -1.17 | 1.18 | 0.90 | 0.91 | Upgrade
|
| Dividend Per Share | - | - | 0.400 | - | - | - | Upgrade
|
| Gross Margin | 36.77% | 36.35% | 42.23% | 38.26% | 40.24% | 41.14% | Upgrade
|
| Operating Margin | -5.43% | -6.32% | 5.67% | 0.69% | 4.87% | 6.58% | Upgrade
|
| Profit Margin | -4.79% | -6.39% | 2.33% | -1.45% | 2.33% | 3.63% | Upgrade
|
| Free Cash Flow Margin | 3.25% | 7.78% | -6.44% | 6.54% | 5.28% | 5.07% | Upgrade
|
| EBITDA | 12.45 | 4.1 | 113.09 | 68.53 | 104.16 | 126.28 | Upgrade
|
| EBITDA Margin | 1.41% | 0.46% | 12.03% | 7.91% | 12.64% | 14.58% | Upgrade
|
| D&A For EBITDA | 60.41 | 60.67 | 59.78 | 62.58 | 64.06 | 69.29 | Upgrade
|
| EBIT | -47.97 | -56.57 | 53.31 | 5.95 | 40.1 | 56.98 | Upgrade
|
| EBIT Margin | -5.43% | -6.32% | 5.67% | 0.69% | 4.87% | 6.58% | Upgrade
|
| Effective Tax Rate | - | - | 20.38% | - | 18.85% | 21.07% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.